Blog

Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC

medpagetoday.com

Jan 11, 2025, 09:17

Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:

“Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC (CM816) Better in terms of pCR, 3y-EFS, and OS BUT The rate of surgery cancellations due to early progression is 16%. ( Nivo+ChT: 6.7%). While pseudoprogression is a factor, such high early progression rates may prevent Nivo+Ipi from routine use.”

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer | Journal of Clinical Oncology

Authors: Mark M. Awad, Patrick M. Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Shun Lu, Tetsuya Mitsudomi, Enriqueta Felip, Stephen R. Broderick, Scott J. Swanson, Julie Brahmer, Keith Kerr, Gene B. Saylors, Ke-Neng Chen, Vishwanath Gharpure, Jaclyn Neely, David Balli, Nan Hu, and Mariano Provencio Pulla.

Neoadjuvant Nivo+ Ipi vs ChT in Resectable NSCLC

cancer Changli Wang David Balli Enriqueta Felip Gene B. Saylors Jaclyn Neely Jonathan Spicer Julie Brahmer Ke-Neng Chen Keith Kerr Mariano Provencio Pulla Mark M. Awad Nan Hu Nicolas Girard OncoDaily Oncology Patrick M Forde Scott J. Swanson Shun Lu Stephen R Broderick Tetsuya Mitsudomi Vishwanath Gharpure Yakup Ergün

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to OncoDaily on Pediatric Oncology Funding